J&J reports 75% tumor response rate in advanced prostate cancer trial
Johnson & Johnson says its JNJ-6143 molecule achieved a 75% tumor response rate in advanced prostate cancer, according to Reuters.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Johnson & Johnson said that in a study of its JNJ-6143 molecule in patients with advanced prostate cancer, the tumor response rate reached 75%. The company describes the compound as a first-in-class RiPTAC molecule.
The information was reported by Reuters.
why it matters
The news concerns a single early-stage drug, so it is unlikely to move the shares of the large pharmaceutical group much. Investors typically wait for confirmation in larger trials before judging the commercial potential of the drug for J&J stock.
tags
instruments
sources
- Johnson & Johnson Reports 75% Tumor Response Rate In Advanced Prostate Cancer With JNJ-6143 — Reuters, 25 October 2026 at 07:31 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗